Clinical trial
Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in…
NCT00298675 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00298675 |
|---|---|
| Title | Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors |
| Official title | A Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | BSI-201 (iniparib), irinotecan |
| Enrollment | 59 |
| Start date | Mar 1, 2006 |
| Primary completion | Jul 1, 2010 |
| Completion | May 1, 2011 |
| First posted | Mar 3, 2006 |
| Last update posted | Aug 2, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: